Trevi Therapeutics, INC Form 4 insider transactions

Director Edward T. Mathers was granted 35,000 nonstatutory stock options in Trevi Therapeutics, Inc.

David P. Meeker, a Director at Trevi Therapeutics, Inc., acquired 35,000 stock options with an exercise price of $13.45.

Trevi Therapeutics, Inc. reports that Director Anne Vanlent was granted stock options for 35,000 shares.

Michael Heffernan, a Director at Trevi Therapeutics, Inc., acquired 35,000 stock options with an exercise price of $13.45, vesting on June 3, 2026.

Trevi Therapeutics' Chief Financial Officer, David C. Hastings, was granted 375,000 stock options with an exercise price of $11.21, vesting over four years.

Christopher Galletta, Trevi Therapeutics' Controller, exercised stock options and acquired common stock under a pre-arranged plan.

Trevi Therapeutics, Inc. director Edward T. Mathers was granted 45,000 nonstatutory stock options with an exercise price of $6.25 per share, as disclosed in a recent SEC Form 4 filing.

Dominick Colangelo, a Director at Trevi Therapeutics, Inc. (TRVI), was granted 45,000 nonstatutory stock options with an exercise price of $6.25 per share.

Trevi Therapeutics, Inc. Director Michael Thomas Heffernan was granted 45,000 nonstatutory stock options with an exercise price of $6.25 per share, set to vest over approximately one year or by the next annual meeting.

Trevi Therapeutics, Inc. Director Anne Vanlent was granted 45,000 nonstatutory stock options with an exercise price of $6.25, vesting over the next year.

Trevi Therapeutics, Inc. Director David P. Meeker was granted 45,000 nonstatutory stock options with an exercise price of $6.25, as reported in a recent SEC Form 4 filing.

A Trevi Therapeutics, Inc. executive's performance-based stock options have vested due to the successful achievement of clinical trial milestones for Haduvio in chronic cough.

Trevi Therapeutics' Chief Scientific Officer, Thomas Sciascia, saw 92,000 performance-based stock options vest following the successful attainment of clinical trial milestones for Haduvio in chronic cough.

Trevi Therapeutics, Inc.'s Chief Financial Officer, Lisa Delfini, saw a significant portion of her performance-based stock options vest following the successful achievement of clinical trial milestones for Haduvio.

Trevi Therapeutics' Chief Commercial Officer, Simon Farrell, saw a significant portion of his performance-based stock options vest following the successful achievement of performance criteria for the company's Phase 2b CORAL and Phase 2 RIVER clinical trials for Haduvio.

Trevi Therapeutics, Inc. President and CEO Jennifer L. Good's performance-based stock options for 102,000 shares vested on May 31, 2025, following the successful achievement of performance criteria related to the company's Phase 2b CORAL trial.

Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, reports the exercise of stock options and subsequent sale of shares on March 25, 2025.

Jennifer Good, CEO of Trevi Therapeutics, reports the exercise of stock options and subsequent sale of common stock.

Trevi Therapeutics CEO Jennifer Good acquired 54,400 shares of common stock on March 10, 2025, following the vesting of a performance-based stock option due to the successful results of the Phase 2 RIVER trial.

Lisa Delfini, CFO of Trevi Therapeutics, acquired 38,400 shares of common stock on March 10, 2025, following the vesting of a performance-based stock option tied to the successful results of the Phase 2 RIVER trial.

Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, acquired 32,000 shares of common stock following the successful results of the Phase 2 RIVER trial.

Christopher Galletta, Controller and Principal Accounting Officer of Trevi Therapeutics, acquired 4,560 shares of common stock following the successful results of the Phase 2 RIVER trial.

Trevi Therapeutics' Chief Commercial Officer, Simon Farrell, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics, was granted stock options for 116,000 shares on February 18, 2025.

James V. Cassella, Chief Development Officer of Trevi Therapeutics, Inc., was granted stock options for 257,500 shares of common stock on February 18, 2025.

Farrell Simon, Chief Commercial Officer of Trevi Therapeutics, was granted stock options for 225,500 shares on February 18, 2025.

Lisa Delfini, CFO of Trevi Therapeutics, was granted stock options to purchase 225,500 shares of common stock on February 18, 2025.

Christopher Galletta, Controller and Principal Accounting Officer of Trevi Therapeutics, Inc., was granted stock options to purchase 41,000 shares of common stock on February 18, 2025.

Trevi Therapeutics CEO Jennifer L. Good was granted stock options to purchase 811,000 shares of common stock on February 18, 2025.

Lisa Delfini, CFO of Trevi Therapeutics, exercised stock options and acquired common stock, as reported in a recent SEC filing.